Cerner Corporation (CERN)
(Delayed Data from NSDQ)
$68.47 USD
+0.46 (0.68%)
Updated May 3, 2019 04:00 PM ET
After-Market: $68.46 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.47 USD
+0.46 (0.68%)
Updated May 3, 2019 04:00 PM ET
After-Market: $68.46 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Cerner (CERN) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Cerner (CERN) first-quarter results benefit from gains in Licensed software, Subscriptions and Professional and Managed services units, and international revenue growth.
Cerner (CERN) Surpasses Q1 Earnings Estimates
by Zacks Equity Research
Cerner (CERN) delivered earnings and revenue surprises of 5.97% and -1.20%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Cerner (CERN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Cerner's (CERN) first-quarter results are likely to reflect solid show by Population Health, Revenue Cycle and IT Works.
Here's Why You Should Hold on to Cerner (CERN) Stock Now
by Zacks Equity Research
Cerner (CERN) continues to gain from solid prospects in EHR and strategic deals. However, margin contraction remains a woe.
Here's Why You Should Retain Cerner (CERN) Stock for Now
by Zacks Equity Research
Cerner (CERN) is gaining traction from prudent strategic deals and big data based EHR system. However, weak margin remains a woe.
Cerner (CERN) Down 6.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Cerner (CERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold on to Cerner (CERN) Stock Now
by Zacks Equity Research
Cerner (CERN) is gaining traction from prudent strategic deals and big data based EHR system. However, weak margins remain a woe.
Cerner (CERN) Catches Eye: Stock Jumps 5.9%
by Zacks Equity Research
Cerner (CERN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Cerner (CERN) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Cerner (CERN) fourth-quarter results benefit from higher revenues, gains in Licensed software, Technology resale, Professional and Managed services units, and international revenue growth.
Cerner (CERN) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Cerner (CERN) delivered earnings and revenue surprises of 1.35% and 0.56%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold on to Nevro (NVRO) Stock for Now
by Zacks Equity Research
Nevro (NVRO) is gaining traction from strengthening international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.
Here's Why You Should Hold on to OPKO Health Stock for Now
by Zacks Equity Research
OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.
Cerner (CERN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Top-line growth and solid show by Population Health, Revenue Cycle and IT Works are likely to have aided Cerner's (CERN) Q4 earnings. However, contraction in gross margin is likely to have been a dampener.
Varian (VAR) Earnings and Revenues Miss Estimates in Q1
by Zacks Equity Research
Varian (VAR) gains from core Oncology segment in fiscal Q1.
Accuray (ARAY) Q2 Earnings Top Estimates, Gross Orders Fall
by Zacks Equity Research
Service revenues drive Accuray's (ARAY) Q2 results, gross margin expands.
Cerner (CERN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Cerner (CERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Add HealthEquity (HQY) to Portfolio Now
by Zacks Equity Research
Solid prospects in the HSA industry consistently drive HealthEquity (HQY).
Here's Why You Should Invest in Intuitive Surgical Stock Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base.
Intuitive Surgical (ISRG) Q4 Earnings Top, Margins Expand
by Zacks Equity Research
Intuitive Surgical (ISRG) gains from solid international show in Q4.
NextGen (NXGN) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
NextGen (NXGN) gains from Recurring revenues in Q3, bookings down.
Here's Why You Should Add DexCom (DXCM) to Your Portfolio
by Zacks Equity Research
DexCom (DXCM) expects its strong product portfolio to consistently drive top line.
ResMed Launches AirFit F30i CPAP Mask, Widens Client Base
by Zacks Equity Research
ResMed (RMD) launches its first tube-up, full-face CPAP mask, thus completing its full-face mask portfolio.
Here's Why You Should Add Veeva (VEEV) to Your Portfolio Now
by Zacks Equity Research
Veeva (VEEV) sees a slew of positive developments.
Nevro (NVRO) Gains Ground on Solid Preliminary Q4 Results
by Zacks Equity Research
Higher revenues and upbeat 2020 worldwide revenue outlook benefit Nevro's (NVRO) preliminary Q4 results.
Allscripts Expands Partnership With PIH Health Through 2025
by Zacks Equity Research
Encouraged by its solid EHR prospects, Allscripts (MDRX) expects a surge in its fourth-quarter 2019 bookings.